Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Firebrick Pharma Limited ( (AU:FRE) ) is now available.
Firebrick Pharma Limited has notified the ASX of a proposed issue of up to 1,000,000 unlisted options as part of a placement or similar capital-raising mechanism. The options will be exercisable at $0.15 and are scheduled to expire on 10 February 2030, indicating a long-dated incentive structure that may support future funding flexibility and align stakeholder interests over the medium term.
The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.
More about Firebrick Pharma Limited
Firebrick Pharma Limited is an ASX-listed pharmaceutical company focused on developing and commercialising health-related products. The company operates within the broader life sciences and biotech sector, using capital market placements and securities issues to support its ongoing activities and growth initiatives.
Average Trading Volume: 97,607
Technical Sentiment Signal: Buy
Current Market Cap: A$17.11M
See more insights into FRE stock on TipRanks’ Stock Analysis page.